Apollomics, Inc. (NASDAQ:APLMW) Sees Large Decline in Short Interest

Apollomics, Inc. (NASDAQ:APLMW) was the target of a large decline in short interest in February. As of February 28th, there was short interest totalling 3,500 shares, a decline of 20.5% from the February 13th total of 4,400 shares. Based on an average daily trading volume, of 29,700 shares, the days-to-cover ratio is presently 0.1 days.

Apollomics Price Performance

Shares of Apollomics stock opened at $0.01 on Wednesday. The stock has a 50 day moving average price of $0.01 and a two-hundred day moving average price of $0.01. Apollomics has a 12-month low of $0.01 and a 12-month high of $0.03.

Apollomics Company Profile

Apollomics, Inc, a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. Its pipeline consists of various development-stage assets, including novel and humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways.